5 million for research in South AfricaFor the 3rd amount of time in four months.

Related StoriesDespite reduced HIV/AIDS deaths, disease still persists in South AfricaMany seasonal allergy victims take OTC items rather prescription medicationsPitt Open public Health launches research to promote health among maturing gay and bisexual men with HIVThe study will involve 350 patients who reside in the Tugela Ferry area of KwaZulu-Natal, South Africa where South African wellness officials estimate 39 % of pregnant women are infected with HIV almost.In addition, we will leverage our neurology knowledge to evaluate NP-1998 for the treating neuropathic pain, with an initial focus on painful diabetic neuropathy. This adds another potentially important, late stage item to our pipeline. Acorda produced an around $8 million payment to obtain development and commercialization rights for Qutenza and NP-1998 in the usa, Canada, Latin America and certain other territories, including $7 million paid to NeurogesX and around $900,000 for certain assumed accounts payable.